ArticleAging2012
Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?
Article in Aging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression.Oncoscience · 2022Article
- From rapalogs to anti-aging formula.Oncotarget · 2017Review
- Do p53 stress responses impact organismal aging?Translational cancer research · 2016Article
- Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-β pathway.Oncotarget · 2016Article
- MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.Oncotarget · 2016Article
- Role of multifaceted regulators in cancer glucose metabolism and their clinical significance.Oncotarget · 2016Review
- Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging.Oncotarget · 2016Article
- Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner.Oncotarget · 2015Article
- Article
- Rejuvenating immunity: "anti-aging drug today" eight years later.Oncotarget · 2015Article
- p53 and rapamycin are additive.Oncotarget · 2015Article
- Development of cancer-initiating cells and immortalized cells with genomic instability.World journal of stem cells · 2015Review
- TAp73 promotes anabolism.Oncotarget · 2014Article
- Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Oncotarget · 2014Article
- Koschei the immortal and anti-aging drugs.Cell death & disease · 2014Review
- Article
- Article
- Small molecule compounds targeting the p53 pathway: are we finally making progress?Apoptosis : an international journal on programmed cell death · 2014Review
- Geroconversion: irreversible step to cellular senescence.Cell cycle (Georgetown, Tex.) · 2014Review
- Rapamycin induces pluripotent genes associated with avoidance of replicative senescence.Cell cycle (Georgetown, Tex.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
I discuss a very obscure activity of p53, namely suppression of senescence (gerosuppression), which is also manifested as anti-hypertrophic, anti-hypermetabolic, anti-inflammatory and anti-secretory effects of p53. But can gerossuppression suppress tumors?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.